Home/ Stocks/ PRME

Prime Medicine, Inc. Common Stock

PRME XNAS

$3.08 +0.20 (+6.78%) ▲ 15-min delayed

Open

$3.00

High

$3.12

Low

$2.97

Volume

1.97M

Market Cap

$532.82M

About Prime Medicine, Inc. Common Stock

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 146 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$856.0K	$-49,122,000	$-0.28
FY 2025	$4.63M	$-201,142,000	$-1.35
Q3 2025	$1.23M	$-50,582,000	$-0.32
Q2 2025	$1.11M	$-52,591,000	$-0.41

Earnings & Analyst Ratings

Next Earnings: Thu, Nov 5, 2026

Calendar →

Related Market News

No specific coverage for PRME yet. Check out our latest market news or earnings calendar.

Get PRME Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Prime Medicine, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.